|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000182636 |
Summary for NDN |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000182636 | Gene symbol | NDN |
| Gene name | necdin, MAGE family member | |
| HGNC | 7675 | |
| Entrez ID | 4692 | |
| Gene type | protein_coding | |
| Synonyms | NDN|HsT16328|PWCR | |
| UniProtAcc | Q99608 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for NDN |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| NDN | 7.33e+02 | -1.10e+00 | 1.94e-01 | -5.67e+00 | 1.39e-08 | 6.47e-08 | LUAD |
| NDN | 8.26e+02 | -1.60e+00 | 4.58e-01 | -3.50e+00 | 4.69e-04 | 1.71e-03 | BLCA |
| Differentially expressed gene analysis between tumor female and normal female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| NDN | 1.00e+03 | -1.86e+00 | 1.00e-01 | -1.86e+01 | 7.27e-77 | 1.56e-75 | BRCA |
| NDN | 4.39e+02 | -1.74e+00 | 3.97e-01 | -4.38e+00 | 1.17e-05 | 7.43e-05 | READ |
Top |
Sex-biased somatic mutation for NDN |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for NDN |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg12138102 | chr15:23688413 | CGI:chr15:23686412-23687451 | promoter | 4.01e-01 | 2.97e-01 | 2.44e+00 | 1.48e-02 | 3.11e-02 | 1.04e-01 |
| BRCA | cg25061289 | chr15:23688473 | CGI:chr15:23686412-23687451 | promoter | 3.63e-01 | 2.33e-01 | 2.91e+00 | 3.64e-03 | 1.79e-02 | 1.30e-01 |
| GBM | cg25061289 | chr15:23688473 | CGI:chr15:23686412-23687451 | promoter | 3.62e-01 | 4.68e-01 | -2.03e+00 | 4.26e-02 | 4.70e-02 | -1.06e-01 |
| ACC | cg12138102 | chr15:23688413 | CGI:chr15:23686412-23687451 | promoter | 6.62e-01 | 5.00e-01 | 2.93e+00 | 3.37e-03 | 1.32e-02 | 1.62e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| LUAD | cg08325271 | chr15:23687855 | CGI:chr15:23686412-23687451 | promoter | 7.11e-01 | 8.65e-01 | -2.83e+00 | 4.60e-03 | 6.98e-03 | -1.54e-01 |
| THCA | cg12138102 | chr15:23688413 | CGI:chr15:23686412-23687451 | promoter | 6.74e-01 | 7.94e-01 | -3.08e+00 | 2.10e-03 | 5.37e-03 | -1.20e-01 |
| THCA | cg25061289 | chr15:23688473 | CGI:chr15:23686412-23687451 | promoter | 6.36e-01 | 7.64e-01 | -3.95e+00 | 7.66e-05 | 4.94e-04 | -1.28e-01 |
| HNSC | cg25061289 | chr15:23688473 | CGI:chr15:23686412-23687451 | promoter | 3.73e-01 | 4.77e-01 | -3.30e+00 | 9.50e-04 | 1.74e-03 | -1.04e-01 |
| LUSC | cg01989224 | chr15:23687611 | CGI:chr15:23686412-23687451 | promoter | 3.98e-01 | 5.00e-01 | -2.50e+00 | 1.24e-02 | 1.64e-02 | -1.03e-01 |
| LUSC | cg16591875 | chr15:23687717 | CGI:chr15:23686412-23687451 | promoter | 6.53e-01 | 7.57e-01 | -2.12e+00 | 3.36e-02 | 3.62e-02 | -1.04e-01 |
| LUSC | cg11872504 | chr15:23687932 | CGI:chr15:23686412-23687451 | promoter | 6.91e-01 | 9.04e-01 | -3.17e+00 | 1.50e-03 | 3.42e-03 | -2.13e-01 |
| COAD | cg11872504 | chr15:23687932 | CGI:chr15:23686412-23687451 | promoter | 7.17e-01 | 8.53e-01 | -2.11e+00 | 3.47e-02 | 3.79e-02 | -1.36e-01 |
| BLCA | cg26740481 | chr15:23685864 | CGI:chr15:23686412-23687451 | UTR,promoter,exon,gene body | 6.40e-01 | 7.83e-01 | -2.16e+00 | 3.12e-02 | 3.46e-02 | -1.43e-01 |
| LIHC | cg24137567 | chr15:23685805 | CGI:chr15:23686412-23687451 | UTR,promoter,exon,gene body | 3.60e-01 | 4.76e-01 | -5.10e+00 | 3.48e-07 | 1.51e-06 | -1.16e-01 |
| LIHC | cg06743811 | chr15:23686304 | CGI:chr15:23686412-23687451 | promoter,exon,CDS,gene body | 4.30e-01 | 5.75e-01 | -4.32e+00 | 1.58e-05 | 4.07e-05 | -1.45e-01 |
| CHOL | cg22694067 | chr15:23687250 | CGI:chr15:23686412-23687451 | UTR,promoter,exon,gene body | 4.82e-01 | 3.56e-01 | 2.73e+00 | 6.38e-03 | 1.82e-02 | 1.26e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg26740481 | chr15:23685864 | CGI:chr15:23686412-23687451 | UTR,promoter,exon,gene body | 6.77e-01 | 8.60e-01 | -7.95e+00 | 1.87e-15 | 7.04e-15 | -1.83e-01 |
| BRCA | cg01989224 | chr15:23687611 | CGI:chr15:23686412-23687451 | promoter | 3.79e-01 | 4.80e-01 | -7.48e+00 | 7.59e-14 | 2.53e-13 | -1.01e-01 |
| BRCA | cg16591875 | chr15:23687717 | CGI:chr15:23686412-23687451 | promoter | 6.94e-01 | 8.01e-01 | -4.50e+00 | 6.84e-06 | 1.17e-05 | -1.08e-01 |
| BRCA | cg11872504 | chr15:23687932 | CGI:chr15:23686412-23687451 | promoter | 6.35e-01 | 8.81e-01 | -1.07e+01 | 1.17e-26 | 1.17e-25 | -2.45e-01 |
| BRCA | cg12138102 | chr15:23688413 | CGI:chr15:23686412-23687451 | promoter | 4.01e-01 | 6.13e-01 | -1.22e+01 | 2.15e-34 | 5.72e-33 | -2.12e-01 |
| BRCA | cg25061289 | chr15:23688473 | CGI:chr15:23686412-23687451 | promoter | 3.63e-01 | 6.30e-01 | -1.27e+01 | 6.55e-37 | 2.68e-35 | -2.66e-01 |
| KIRC | cg24137567 | chr15:23685805 | CGI:chr15:23686412-23687451 | UTR,promoter,exon,gene body | 4.25e-01 | 5.27e-01 | -2.55e+00 | 1.08e-02 | 1.80e-02 | -1.02e-01 |
| LUAD | cg01989224 | chr15:23687611 | CGI:chr15:23686412-23687451 | promoter | 4.52e-01 | 5.57e-01 | -3.04e+00 | 2.37e-03 | 5.73e-03 | -1.05e-01 |
| COAD | cg01989224 | chr15:23687611 | CGI:chr15:23686412-23687451 | promoter | 5.44e-01 | 4.31e-01 | 2.27e+00 | 2.30e-02 | 2.88e-02 | 1.12e-01 |
| BLCA | cg16591875 | chr15:23687717 | CGI:chr15:23686412-23687451 | promoter | 6.40e-01 | 7.59e-01 | -2.20e+00 | 2.76e-02 | 3.35e-02 | -1.19e-01 |
| KIRP | cg25061289 | chr15:23688473 | CGI:chr15:23686412-23687451 | promoter | 5.48e-01 | 6.88e-01 | -2.31e+00 | 2.08e-02 | 2.75e-02 | -1.40e-01 |
Top |
Exon skipping events with PSI in TCGA for NDN |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for NDN |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for NDN |
| TFs related to NDN. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| CHOL | ZNF571 | NDN | 3.07e+00 | 4.71e-03 | 4.19e+00 | 9.86e-01 | Female-biased |
| MESO | ZNF418 | NDN | 3.33e+00 | 1.44e-03 | 5.18e+00 | 9.96e-01 | Female-biased |
| NDN related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for NDN |
| RBPs related to ES in NDN. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| NDN related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs74005944 | chr15:33665923:C:G | - | 0.157289830050038 | 0.0449979934740275 | HNSC | Female-baised eQTL |
| rs73365884 | chr15:29471760:C:T | - | 0.359712130942708 | 0.000143759586614372 | GBM | Female-baised eQTL |
| rs74008480 | chr15:29473811:G:A | - | 0.359712130942708 | 0.000143759586614372 | GBM | Female-baised eQTL |
| rs73365895 | chr15:29474064:T:C | - | 0.359712130942708 | 0.000143759586614372 | GBM | Female-baised eQTL |
| rs7175986 | chr15:32740906:A:G | - | 0.304788657826885 | 0.000254316783034832 | GBM | Female-baised eQTL |
| rs28436730 | chr15:32743909:C:T | - | 0.304788657826885 | 0.000254316783034832 | GBM | Female-baised eQTL |
| rs1655656 | chr15:29392930:T:A | - | 0.297008623974585 | 0.00402099591857233 | GBM | Female-baised eQTL |
| rs533554 | chr15:29393136:G:T | - | 0.297008623974585 | 0.00402099591857233 | GBM | Female-baised eQTL |
| rs17115228 | chr15:25103709:C:G | - | 0.247344368278058 | 0.0131619743703381 | GBM | Female-baised eQTL |
| rs8025274 | chr15:28990643:T:G | - | 0.200100687829909 | 0.0315791911794039 | GBM | Female-baised eQTL |
| rs58959759 | chr15:28955936:A:G | - | 0.200058473695089 | 0.0317007344498224 | GBM | Female-baised eQTL |
| rs8033952 | chr15:28136577:C:A | - | -0.197698761917341 | 0.0383365756251247 | GBM | Female-baised eQTL |
| rs8040272 | chr15:24578869:A:G | - | 0.149619887272168 | 0.0425101233231854 | GBM | Female-baised eQTL |
| rs76699450 | chr15:24041641:G:A | - | 0.188757705601027 | 0.0446888742303238 | GBM | Female-baised eQTL |
| rs60251681 | chr15:24042365:G:A | - | 0.188757705601027 | 0.0446888742303238 | GBM | Female-baised eQTL |
| rs139170165 | chr15:24046788:C:G | - | 0.188757705601027 | 0.0446888742303238 | GBM | Female-baised eQTL |
| rs149001760 | chr15:24047422:T:C | - | 0.188757705601027 | 0.0446888742303238 | GBM | Female-baised eQTL |
| rs143843965 | chr15:24047426:A:G | - | 0.188757705601027 | 0.0446888742303238 | GBM | Female-baised eQTL |
| rs10519646 | chr15:29310799:C:T | - | 0.19941759685776 | 0.0488939899393913 | GBM | Female-baised eQTL |
| rs11638932 | chr15:24828607:A:G | - | 0.0997309711224149 | 0.0352451226657753 | LUSC | Female-baised eQTL |
| rs75243807 | chr15:24829114:A:C | - | 0.0986729733574533 | 0.0462725681001926 | LUSC | Female-baised eQTL |
| rs75066798 | chr15:24830781:G:C | - | 0.0983440211769708 | 0.0488825370284566 | LUSC | Female-baised eQTL |
| rs140984085 | chr15:24837625:A:T | - | 0.0966326232415253 | 0.0496119318420555 | LUSC | Female-baised eQTL |
| rs140958366 | chr15:24838016:C:T | - | 0.0966326232415253 | 0.0496119318420555 | LUSC | Female-baised eQTL |
| rs11629898 | chr15:24843988:G:A | - | 0.0966326232415253 | 0.0496119318420555 | LUSC | Female-baised eQTL |
| rs11634286 | chr15:24846619:C:G | - | 0.0966326232415253 | 0.0496119318420555 | LUSC | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs114484885 | chr15:26075643:T:C | - | 0.0783242119659179 | 0.0398667075309238 | LIHC | Male-baised eQTL |
| rs78649218 | chr15:26076450:C:T | - | 0.0783242119659179 | 0.0398667075309238 | LIHC | Male-baised eQTL |
| rs79496313 | chr15:26076787:T:C | - | 0.077738031882948 | 0.0456655355249182 | LIHC | Male-baised eQTL |
| rs77993860 | chr15:26076855:G:A | - | 0.077738031882948 | 0.0456655355249182 | LIHC | Male-baised eQTL |
| rs3897710 | chr15:26077831:G:A | - | 0.077738031882948 | 0.0456655355249182 | LIHC | Male-baised eQTL |
| rs12905276 | chr15:29155009:G:A | - | 0.065118981519633 | 0.031138377564175 | LUAD | Male-baised eQTL |
| rs7174078 | chr15:29154944:A:G | - | 0.0642235494426367 | 0.0373042360779884 | LUAD | Male-baised eQTL |
| rs17604644 | chr15:31838818:T:G | - | 0.0696710387150105 | 0.030755325393989 | COAD | Male-baised eQTL |
| rs7178899 | chr15:31247694:C:T | - | 0.095384079688402 | 0.0324982169740545 | COAD | Male-baised eQTL |
| rs17604629 | chr15:31820466:T:C | - | 0.0692452819334435 | 0.033915724881186 | COAD | Male-baised eQTL |
| rs35575383 | chr15:31808848:T:C | - | 0.068425745174774 | 0.0426899949472214 | COAD | Male-baised eQTL |
| rs11638384 | chr15:31812939:G:A | - | 0.0680499114381089 | 0.0433566546466814 | COAD | Male-baised eQTL |
| rs12904569 | chr15:31811143:A:C | - | 0.066757187276678 | 0.049898781837382 | COAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000182636 |
| CpG Site: cg06743811 | |
| Position to Gene: gene,exon,CDS,promoter | |
| Male Effect: - | |
| Female Effect: -0.42708576486846 | |
 | Gene ID: ENSG00000182636 |
| CpG Site: cg08325271 | |
| Position to Gene: promoter | |
| Male Effect: - | |
| Female Effect: -0.42212117784657 | |
 | Gene ID: ENSG00000182636 |
| CpG Site: cg13828758 | |
| Position to Gene: gene,exon,promoter,UTR | |
| Male Effect: -0.435314812793382 | |
| Female Effect: - | |
 | Gene ID: ENSG00000182636 |
| CpG Site: cg13828758 | |
| Position to Gene: gene,exon,promoter,UTR | |
| Male Effect: -0.447719999463829 | |
| Female Effect: - | |
 | Gene ID: ENSG00000182636 |
| CpG Site: cg22694067 | |
| Position to Gene: gene,exon,promoter,UTR | |
| Male Effect: -0.267555638016573 | |
| Female Effect: - |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg13828758 | chr15:23687226 | gene,exon,promoter,UTR | -0.435314812793382 | 3.2925329406582e-13 | -0.5164414848428276 | 1.330101797394543e-16 | LUAD |
| cg13828758 | chr15:23687226 | gene,exon,promoter,UTR | -0.447719999463829 | 1.03203478821881e-08 | -0.37364833740933445 | 1.42575508425783e-10 | LUSC |
| cg22694067 | chr15:23687250 | gene,exon,promoter,UTR | -0.267555638016573 | 5.2126019216807e-06 | -0.3181853639945138 | 6.547177994980591e-08 | LUSC |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg06743811 | chr15:23686304 | gene,exon,CDS,promoter | -0.42708576486846 | 1.72327016691315e-09 | -0.6940142219077008 | 9.496933696403657e-13 | PAAD |
| cg08325271 | chr15:23687855 | promoter | -0.42212117784657 | 3.15096247336501e-09 | -0.7080450147528071 | 5.007433698139581e-12 | PAAD |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of NDN |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000182636 | NDN | C0007097 | Carcinoma | 1 | CTD_human |
| ENSG00000182636 | NDN | C0024667 | Animal Mammary Neoplasms | 1 | CTD_human |
| ENSG00000182636 | NDN | C0032897 | Prader-Willi Syndrome | 1 | CTD_human |
| ENSG00000182636 | NDN | C0205696 | Anaplastic carcinoma | 1 | CTD_human |
| ENSG00000182636 | NDN | C0205697 | Carcinoma, Spindle-Cell | 1 | CTD_human |
| ENSG00000182636 | NDN | C0205698 | Undifferentiated carcinoma | 1 | CTD_human |
| ENSG00000182636 | NDN | C0205699 | Carcinomatosis | 1 | CTD_human |
| ENSG00000182636 | NDN | C0265222 | Royer Syndrome | 1 | CTD_human |
| ENSG00000182636 | NDN | C1257925 | Mammary Carcinoma, Animal | 1 | CTD_human |
